6/9/25 We are currently making changes to reflect the new Health Sciences Division structure. Thank you for your patience while we make the transition.

Sign in
Back
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry
Journal article   Open access   Peer reviewed

Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry

Ryan C Ungaro, Erica J Brenner, Manasi Agrawal, Xian Zhang, Michael D Kappelman, Jean-Frederic Colombel, Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group and Richard Blair Gearry
Gastroenterology (New York, N.Y. 1943), Vol.162(1), pp.316-319.e5
01/01/2022
DOI: https://doi.org/10.1053/j.gastro.2021.09.011
Handle:
https://hdl.handle.net/10523/20185

Abstract

Adrenal Cortex Hormones - adverse effects COVID-19 - complications COVID-19 - mortality Humans Inflammatory Bowel Diseases - drug therapy Mesalamine - adverse effects Registries SARS-CoV-2 Severity of Illness Index Sulfasalazine - adverse effects Tumor Necrosis Factor-alpha - antagonists & inhibitors
url
https://doi.org/10.1053/j.gastro.2021.09.011View
Published (Version of record) Open

Metrics

13 Record Views
53 Times Cited - Web of Science

Details

Logo image